What question did this study set out to answer?

To evaluate the safety and efficacy of IMC-002 in patients with advanced triple negative breast cancer (TNBC).

May 29, 2026

Phase 1b dose-expansion study of IMC-002, a anti-CD47 monoclonal antibody, in patients with advanced triple negative breast cancer (TNBC).

Key Points

To evaluate the safety and efficacy of IMC-002 in patients with advanced triple negative breast cancer (TNBC).
Phase 1b expansion trial with advanced TNBC patients who progressed after ≥1 prior therapy.
IMC-002 administered at 20 mg/kg Q3W in combination with gemcitabine plus carboplatin or paclitaxel.
Tumor responses assessed every 6 weeks using RECIST 1.1 and analysis of ctDNA for biomarkers.
Overall response rate (ORR) was 25%, disease control rate (DCR) was 75%, and clinical benefit rate (CBR) was 42%.
Grade 3 hematologic adverse events reported included anemia (6 cases) and hemolytic anemia (5 cases).
No clear association between blood-based tumor mutational burden (bTMB) and clinical activity was observed.

Abstract

2524 Background: IMC-002 is a novel therapeutic agent with a distinct mechanism of action. In a phase 1a dose-escalation study, IMC-002 demonstrated favorable safety and tolerability, and clinical activity was observed in patients with hepatocellular carcinoma (HCC) in a subsequent phase 1b trial. Here, we present results from the phase 1b expansion cohort in patients with triple-negative breast cancer (TNBC), focusing on safety, efficacy, and analyses of soluble biomarkers. Methods: Eligible pts had advanced TNBC with progression after ≥1 prior systemic therapy and ECOG PS ≤1. IMC-002 (20 mg/kg Q3W) was administered in combination with gemcitabine plus carboplatin or paclitaxel and continued until disease progression. Tumor response was assessed every 6 weeks per RECIST 1.1 and iRECIST. Baseline ctDNA was analyzed using the AlphaLiquid 1000 platform (1,023 -gene panel). To exclude germline and clonal hematopoiesis of indeterminate potential (CHIP) variants, paired PBMC sequencing was performed. The assay detected single nucleotide variants (SNVs), small insertions and deletions (INDELs), fusions, copy number alterations (CNAs), microsatellite instability (MSI), and blood-based tumor mutational burden (bTMB). Results: A total of 12 pts with advanced TNBC received IMC-002 in combination with gemcitabine plus carboplatin (n=9) or paclitaxel (n=3). Most pts had received ≥2 prior systemic therapy (n=11), and ECOG PS 1 was observed in 10 pts. TRAEs reported in > 1 pt included grade 3 hematologic events, namely anemia (n=6) and hemolytic anemia (n=5). Non-hematologic TRAEs were limited to grade 1–2 and included skin rash (n=9), vitreous floaters (n=4), photopsia (n=3), and IRR (n=2). Among 12 efficacy-evaluable pts, the ORR was 25%, the DCR was 75%, and the CBR (disease control ≥ 6 months) was 42%. Exploratory ctDNA analyses identified no MSI-H tumors. One patient with a partial response was BRCA-positive. Patients achieving clinical benefit showed a higher median maximum somatic allele frequency (MSAF) than those without clinical benefit (32.65 vs 1.00; p=0.19). No clear association between bTMB and clinical activity was observed. Conclusions: IMC-002 in combination with gemcitabine plus carboplatin or paclitaxel demonstrated encouraging antitumor activity with a manageable safety profile in heavily pretreated patients with advanced TNBC. Exploratory baseline ctDNA analyses did not identify molecular features clearly associated with clinical benefit. Clinical trial information: NCT05276310 .

Mark Helpful

Bookmark

Relay